Curanex Pharmaceuticals (CURX) risk factors, FY2025 10-K

Risks Related to Our Business

1. 01We have a limited operating history in an evolving industry, which makes it difficult to evaluate our future prospects and may increase the risk that we will not be successful
2. 02If we fail to raise capital when needed it will have a material adverse effect on our business, financial condition and results of operations

Risks Related to Protection of Intellectual Property Rights

1. 03If we are unable to obtain patent protection for our lead product candidate, to successfully develop and commercialize Phyto-N, our ability to sustain future operations will be significantly diminished
2. 04Any failure in our clinical trials could impair the commercial prospects for our development of Phyto-N
3. 05Our success is largely dependent on our ability to obtain and maintain patent protection and preserve trade secrets, which cannot be guaranteed. Failure to obtain and maintain effective registration of non-provisional utility patents in the United States will have a significant adverse effect on our business
4. 06Any litigation of this nature, regardless of outcome or merit, could result in substantial costs and diversion of management and technical resources, any of which could adversely affect our business and operating results
5. 07Claims by other companies that we infringe on their proprietary technology may result in liability for damages or stop our development and commercialization efforts
6. 08We may be subject to substantial costs stemming from our defense against third-party intellectual property infringement claims
7. 09We may enter into collaboration agreements for the development of products and business development, which could expose us to the risk of reliance on the viability of third parties
8. 10There is no assurance we will be profitable
9. 11We may not have the ability to manage its growth
10. 12We may engage in acquisition activity, which could have adverse effects on its business
11. 13We will rely on third parties for the manufacturing of our clinical drug supplies, and we may face various risks and uncertainties based on our dependence on these manufacturers, which may impair the development of our drug candidates
12. 14We rely on the performance of highly skilled personnel, and if we are unable to attract, retain and motivate well-qualified employees, our business could be harmed
13. 15Our management does not have experience as senior management of a public company or ensuring compliance with public company obligations, and fulfilling these obligations will be expensive and time consuming, which may divert management’s attention from the day-to-day operation of its business
14. 16We may become a party to various legal proceedings, which could have a material adverse effect on our business, financial condition or results of operations
15. 17We may be subject to personal injury, workers’ compensation, discrimination, harassment, wrongful termination, wage and hour, and other claims in the ordinary course of business

Risks Related to the Regulation of Our Business and Products

1. 18Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results
2. 19The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed
3. 20We are heavily dependent on the success of Phyto-N, our lead product candidate, Phyto-N. We cannot give any assurance that Phyto-N will proceed to clinical development or that it will receive regulatory approval, which is necessary before we can commercialize it
4. 21The development and approval process for botanical drugs involves unique challenges and regulatory considerations that may result in additional costs, delays, or failure to obtain regulatory approval
5. 22We may encounter substantial delays in our clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities
6. 23We may fail to sufficiently and promptly respond to clinical demand and market changes in the pharmaceutical industry
7. 24We face risks related to compliance with corporate governance laws and financial reporting standards
8. 25Events such as natural disasters, industrial accidents, epidemics, pandemics, war and acts of terrorism, and adverse weather conditions could disrupt our business or the business of our customers, which could significantly harm our operations, financial results and cash flow
9. 26Changes to U.S. tariff and import/export regulations and inflation may adversely affect our operations and financial results

Risks Relating to Ownership of Our Securities

1. 27We may not be able to satisfy the listing requirements of Nasdaq to maintain a listing of our Common Stock
2. 28If our Common Stock becomes subject to the penny stock rules, it may be more difficult to sell our Common Stock
3. 29A possible “short squeeze” due to a sudden increase in demand of our Common Stock that largely exceeds supply may lead to price volatility in our Common Stock
4. 30Our founders will continue to own a significant percentage of our Common Stock and our Series A Preferred Stock and will be able to exert significant control over matters subject to shareholder approval
5. 31The Company incurs significant increased expenses and administrative burdens as a public company, which could have an adverse effect on its business, financial condition and results of operations
6. 32Prior to the closing of the IPO there was no public market for our Common Stock, and there is no assurance that an active market for our Common Stock may develop
7. 33Our failure to maintain effective internal controls over financial reporting could have an adverse impact on us
8. 34Our financial controls and procedures may not be sufficient to ensure timely and reliable reporting of financial information, which, as a public company, could materially harm our stock price
9. 35We must implement additional and expensive procedures and controls in order to grow our business and organization and to satisfy new reporting requirements, which will increase our costs and require additional management resources
10. 36We are an “emerging growth company” under the JOBS Act of 2012 and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors
11. 37As long as our officers and directors, either individually or in the aggregate, own at least 50% of the voting power of our Company, we are a “controlled company” as defined under the listing rules of Nasdaq
12. 38We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock
13. 39If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline